| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombotic Thrombocytopenic | 57 | 2022 | 216 | 6.120 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 24 | 2019 | 94 | 3.350 |
Why?
|
| Hemolytic-Uremic Syndrome | 26 | 2015 | 81 | 2.630 |
Why?
|
| Registries | 34 | 2017 | 383 | 1.950 |
Why?
|
| Adolescent Behavior | 20 | 2016 | 67 | 1.940 |
Why?
|
| ADAM Proteins | 28 | 2015 | 102 | 1.690 |
Why?
|
| Plasma Exchange | 31 | 2020 | 103 | 1.670 |
Why?
|
| Hematology | 10 | 2021 | 24 | 1.620 |
Why?
|
| ADAMTS13 Protein | 36 | 2022 | 126 | 1.610 |
Why?
|
| Humans | 188 | 2022 | 26826 | 1.580 |
Why?
|
| Thrombocytopenia | 12 | 2018 | 113 | 1.410 |
Why?
|
| Adolescent | 68 | 2021 | 2957 | 1.400 |
Why?
|
| Female | 123 | 2021 | 14462 | 1.360 |
Why?
|
| Venous Thromboembolism | 5 | 2021 | 132 | 1.190 |
Why?
|
| Adult | 85 | 2021 | 7382 | 1.130 |
Why?
|
| Male | 104 | 2021 | 12869 | 1.110 |
Why?
|
| Oklahoma | 37 | 2019 | 973 | 1.040 |
Why?
|
| Evidence-Based Medicine | 8 | 2021 | 140 | 1.030 |
Why?
|
| von Willebrand Diseases | 3 | 2020 | 4 | 1.010 |
Why?
|
| Parent-Child Relations | 10 | 2015 | 70 | 0.940 |
Why?
|
| Middle Aged | 63 | 2021 | 6817 | 0.850 |
Why?
|
| Sexual Behavior | 9 | 2020 | 87 | 0.840 |
Why?
|
| Risk-Taking | 15 | 2016 | 57 | 0.830 |
Why?
|
| Prospective Studies | 21 | 2020 | 1216 | 0.830 |
Why?
|
| Pregnancy Complications, Hematologic | 5 | 2018 | 38 | 0.810 |
Why?
|
| Residence Characteristics | 5 | 2014 | 101 | 0.790 |
Why?
|
| Child | 32 | 2019 | 2147 | 0.790 |
Why?
|
| Pregnancy in Adolescence | 7 | 2020 | 29 | 0.780 |
Why?
|
| Platelet Count | 15 | 2018 | 112 | 0.750 |
Why?
|
| Aged | 49 | 2021 | 5166 | 0.740 |
Why?
|
| Anticoagulants | 4 | 2018 | 293 | 0.720 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 67 | 0.720 |
Why?
|
| Quality of Life | 5 | 2019 | 464 | 0.710 |
Why?
|
| Pregnancy | 18 | 2020 | 1131 | 0.710 |
Why?
|
| Antifibrinolytic Agents | 2 | 2019 | 22 | 0.710 |
Why?
|
| Postpartum Hemorrhage | 1 | 2020 | 9 | 0.690 |
Why?
|
| Young Adult | 30 | 2021 | 2581 | 0.680 |
Why?
|
| Thrombosis | 4 | 2020 | 147 | 0.680 |
Why?
|
| Rituximab | 10 | 2020 | 60 | 0.660 |
Why?
|
| Hemorrhage | 9 | 2017 | 259 | 0.640 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2014 | 66 | 0.640 |
Why?
|
| Tranexamic Acid | 1 | 2019 | 13 | 0.630 |
Why?
|
| Menorrhagia | 4 | 2019 | 5 | 0.630 |
Why?
|
| Risk Factors | 18 | 2019 | 2010 | 0.600 |
Why?
|
| Tobacco Use Disorder | 4 | 2014 | 115 | 0.600 |
Why?
|
| Social Environment | 4 | 2014 | 56 | 0.570 |
Why?
|
| Surveys and Questionnaires | 22 | 2019 | 918 | 0.560 |
Why?
|
| Alcohol Drinking | 2 | 2016 | 162 | 0.550 |
Why?
|
| Sex Education | 5 | 2018 | 14 | 0.540 |
Why?
|
| Driving Under the Influence | 1 | 2016 | 3 | 0.540 |
Why?
|
| Recurrence | 16 | 2017 | 316 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2018 | 160 | 0.540 |
Why?
|
| Blood Alcohol Content | 1 | 2016 | 5 | 0.540 |
Why?
|
| Adrenal Cortex Hormones | 8 | 2020 | 74 | 0.530 |
Why?
|
| Contraception | 5 | 2020 | 21 | 0.530 |
Why?
|
| Genital Neoplasms, Female | 4 | 2019 | 61 | 0.520 |
Why?
|
| Treatment Outcome | 18 | 2020 | 2264 | 0.520 |
Why?
|
| Societies, Medical | 2 | 2016 | 89 | 0.520 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 40 | 0.510 |
Why?
|
| Socioeconomic Factors | 9 | 2017 | 242 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 233 | 0.490 |
Why?
|
| Family Characteristics | 6 | 2015 | 46 | 0.490 |
Why?
|
| Thrombotic Microangiopathies | 4 | 2017 | 24 | 0.480 |
Why?
|
| Tobacco, Smokeless | 2 | 2013 | 43 | 0.470 |
Why?
|
| Substance-Related Disorders | 4 | 2014 | 166 | 0.470 |
Why?
|
| Quinine | 5 | 2017 | 23 | 0.470 |
Why?
|
| United States | 16 | 2021 | 2032 | 0.450 |
Why?
|
| Psychology, Adolescent | 4 | 2009 | 13 | 0.450 |
Why?
|
| Tobacco Use | 1 | 2015 | 83 | 0.450 |
Why?
|
| Retrospective Studies | 22 | 2020 | 2433 | 0.450 |
Why?
|
| Metalloendopeptidases | 6 | 2005 | 39 | 0.450 |
Why?
|
| Longitudinal Studies | 9 | 2016 | 400 | 0.440 |
Why?
|
| Group Homes | 3 | 2018 | 4 | 0.440 |
Why?
|
| Sex Factors | 8 | 2020 | 445 | 0.440 |
Why?
|
| Contraception Behavior | 5 | 2020 | 15 | 0.440 |
Why?
|
| Age Factors | 13 | 2018 | 716 | 0.430 |
Why?
|
| Health Behavior | 5 | 2011 | 154 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 316 | 0.410 |
Why?
|
| Cotinine | 2 | 2013 | 45 | 0.410 |
Why?
|
| Saliva | 2 | 2013 | 94 | 0.410 |
Why?
|
| African Americans | 4 | 2011 | 350 | 0.400 |
Why?
|
| Seasons | 1 | 2012 | 83 | 0.390 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2015 | 41 | 0.390 |
Why?
|
| Child, Preschool | 15 | 2019 | 1091 | 0.390 |
Why?
|
| ABO Blood-Group System | 1 | 2011 | 7 | 0.380 |
Why?
|
| Academic Success | 2 | 2021 | 8 | 0.370 |
Why?
|
| Single-Domain Antibodies | 2 | 2020 | 7 | 0.360 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 1927 | 0.350 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2018 | 279 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 357 | 0.320 |
Why?
|
| Cohort Studies | 11 | 2019 | 857 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2017 | 67 | 0.300 |
Why?
|
| Social Support | 5 | 2014 | 123 | 0.300 |
Why?
|
| Thromboembolism | 3 | 2017 | 57 | 0.300 |
Why?
|
| Mass Screening | 2 | 2019 | 141 | 0.290 |
Why?
|
| Autoantibodies | 5 | 2020 | 466 | 0.290 |
Why?
|
| Glucocorticoids | 3 | 2006 | 114 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 309 | 0.290 |
Why?
|
| Cognition Disorders | 3 | 2015 | 181 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 367 | 0.280 |
Why?
|
| Coitus | 5 | 2015 | 14 | 0.280 |
Why?
|
| Risk Assessment | 4 | 2019 | 587 | 0.280 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 980 | 0.280 |
Why?
|
| Pre-Eclampsia | 3 | 2015 | 48 | 0.280 |
Why?
|
| Databases, Factual | 6 | 2019 | 250 | 0.270 |
Why?
|
| Purpura, Thrombocytopenic | 2 | 2008 | 6 | 0.270 |
Why?
|
| Parents | 8 | 2014 | 122 | 0.270 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 445 | 0.270 |
Why?
|
| Palliative Care | 2 | 2019 | 79 | 0.260 |
Why?
|
| Guideline Adherence | 2 | 2018 | 91 | 0.260 |
Why?
|
| Renal Veins | 2 | 2018 | 7 | 0.260 |
Why?
|
| Review Literature as Topic | 2 | 2014 | 9 | 0.260 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 78 | 0.260 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2017 | 16 | 0.260 |
Why?
|
| Logistic Models | 7 | 2015 | 397 | 0.250 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 657 | 0.250 |
Why?
|
| Biomarkers | 6 | 2016 | 733 | 0.250 |
Why?
|
| Patient Selection | 3 | 2018 | 143 | 0.250 |
Why?
|
| Medical Records | 2 | 2017 | 49 | 0.250 |
Why?
|
| Platelet Transfusion | 4 | 2013 | 29 | 0.240 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 205 | 0.240 |
Why?
|
| Life Change Events | 2 | 2015 | 33 | 0.240 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 456 | 0.240 |
Why?
|
| von Willebrand Factor | 3 | 2020 | 36 | 0.240 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 34 | 0.230 |
Why?
|
| Benchmarking | 1 | 2004 | 28 | 0.230 |
Why?
|
| Midwestern United States | 11 | 2013 | 38 | 0.230 |
Why?
|
| Academies and Institutes | 3 | 2021 | 15 | 0.230 |
Why?
|
| Communication | 7 | 2020 | 167 | 0.220 |
Why?
|
| Depression | 2 | 2016 | 211 | 0.220 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 910 | 0.220 |
Why?
|
| Infant, Newborn | 7 | 2019 | 843 | 0.220 |
Why?
|
| Splenectomy | 5 | 2013 | 43 | 0.220 |
Why?
|
| Drug Therapy, Combination | 2 | 2003 | 203 | 0.220 |
Why?
|
| Sexual Abstinence | 4 | 2011 | 6 | 0.220 |
Why?
|
| Dexamethasone | 1 | 2003 | 53 | 0.220 |
Why?
|
| Infant | 10 | 2019 | 957 | 0.210 |
Why?
|
| Databases as Topic | 1 | 2003 | 21 | 0.210 |
Why?
|
| Administration, Oral | 3 | 2019 | 166 | 0.210 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 38 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2003 | 140 | 0.200 |
Why?
|
| Disease Progression | 3 | 2019 | 450 | 0.200 |
Why?
|
| Postpartum Period | 2 | 2020 | 63 | 0.200 |
Why?
|
| Indians, North American | 4 | 2019 | 511 | 0.200 |
Why?
|
| Sepsis | 3 | 2012 | 81 | 0.200 |
Why?
|
| Menstruation | 2 | 2019 | 9 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 507 | 0.200 |
Why?
|
| Pregnancy Outcome | 3 | 2015 | 128 | 0.200 |
Why?
|
| Pulmonary Embolism | 2 | 2018 | 126 | 0.200 |
Why?
|
| Blood Platelets | 3 | 2011 | 203 | 0.190 |
Why?
|
| Muscle Relaxants, Central | 2 | 2017 | 11 | 0.190 |
Why?
|
| Unsafe Sex | 2 | 2013 | 6 | 0.190 |
Why?
|
| Sexual Partners | 1 | 2001 | 24 | 0.190 |
Why?
|
| Remission Induction | 5 | 2017 | 50 | 0.190 |
Why?
|
| Hematoma | 1 | 2021 | 26 | 0.190 |
Why?
|
| Demography | 6 | 2017 | 91 | 0.190 |
Why?
|
| Acute Kidney Injury | 3 | 2017 | 73 | 0.190 |
Why?
|
| Puerperal Disorders | 1 | 2021 | 14 | 0.190 |
Why?
|
| Sirtuin 3 | 1 | 2021 | 18 | 0.190 |
Why?
|
| Pelvic Floor Disorders | 1 | 2021 | 21 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 147 | 0.190 |
Why?
|
| Catalase | 1 | 2021 | 49 | 0.190 |
Why?
|
| Delivery, Obstetric | 1 | 2021 | 38 | 0.180 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 50 | 0.180 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 61 | 0.180 |
Why?
|
| Prognosis | 7 | 2017 | 759 | 0.180 |
Why?
|
| Radiosurgery | 2 | 2019 | 78 | 0.180 |
Why?
|
| Hospitalization | 3 | 2019 | 189 | 0.180 |
Why?
|
| Prevalence | 8 | 2022 | 472 | 0.180 |
Why?
|
| Vitamin K | 2 | 2012 | 39 | 0.180 |
Why?
|
| Research Design | 4 | 2018 | 174 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 139 | 0.180 |
Why?
|
| Religion and Sex | 1 | 2020 | 2 | 0.170 |
Why?
|
| Christianity | 1 | 2020 | 3 | 0.170 |
Why?
|
| Religion and Medicine | 1 | 2020 | 6 | 0.170 |
Why?
|
| Social Class | 2 | 2019 | 78 | 0.170 |
Why?
|
| Laboratories | 1 | 2020 | 18 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 298 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2019 | 49 | 0.170 |
Why?
|
| Brain Edema | 1 | 2019 | 22 | 0.170 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 273 | 0.170 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 278 | 0.170 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 29 | 0.160 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2019 | 1 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2019 | 2 | 0.160 |
Why?
|
| Alleles | 2 | 2019 | 345 | 0.160 |
Why?
|
| Homozygote | 1 | 2019 | 36 | 0.160 |
Why?
|
| Stroke | 1 | 2022 | 233 | 0.160 |
Why?
|
| Venous Thrombosis | 2 | 2018 | 98 | 0.160 |
Why?
|
| Prednisone | 5 | 2014 | 51 | 0.160 |
Why?
|
| Purpura Fulminans | 1 | 2018 | 1 | 0.160 |
Why?
|
| Anemia, Hemolytic | 2 | 2017 | 22 | 0.160 |
Why?
|
| Heterozygote | 1 | 2019 | 64 | 0.160 |
Why?
|
| Central Venous Catheters | 1 | 2018 | 6 | 0.160 |
Why?
|
| Portal Vein | 1 | 2018 | 8 | 0.160 |
Why?
|
| Antithrombins | 1 | 2018 | 28 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 37 | 0.160 |
Why?
|
| HIV Infections | 2 | 2012 | 146 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 130 | 0.160 |
Why?
|
| Hysterectomy | 1 | 2019 | 80 | 0.160 |
Why?
|
| Meningeal Neoplasms | 1 | 2019 | 73 | 0.150 |
Why?
|
| Educational Status | 2 | 2017 | 110 | 0.150 |
Why?
|
| Immunologic Factors | 2 | 2016 | 48 | 0.150 |
Why?
|
| Meningioma | 1 | 2019 | 79 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 586 | 0.150 |
Why?
|
| Specialization | 2 | 2018 | 19 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 38 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 18 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 26 | 0.150 |
Why?
|
| Placenta | 1 | 2018 | 74 | 0.150 |
Why?
|
| United Kingdom | 2 | 2015 | 70 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 131 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 133 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2015 | 986 | 0.150 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2017 | 9 | 0.150 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 9 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 472 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 18 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 5 | 0.150 |
Why?
|
| Signal Transduction | 2 | 2021 | 1344 | 0.150 |
Why?
|
| Medical Oncology | 2 | 2014 | 85 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 42 | 0.140 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 102 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2017 | 51 | 0.140 |
Why?
|
| Family | 2 | 2014 | 98 | 0.140 |
Why?
|
| Interviews as Topic | 8 | 2015 | 150 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 105 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 98 | 0.140 |
Why?
|
| Contraceptive Agents | 1 | 2016 | 8 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 277 | 0.140 |
Why?
|
| Mobile Applications | 1 | 2017 | 58 | 0.140 |
Why?
|
| Primary Myelofibrosis | 1 | 2016 | 9 | 0.140 |
Why?
|
| Isoantibodies | 3 | 2013 | 15 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 32 | 0.140 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 10 | 0.140 |
Why?
|
| Clostridium Infections | 1 | 2017 | 66 | 0.140 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 213 | 0.140 |
Why?
|
| Automobile Driving | 1 | 2016 | 9 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 104 | 0.130 |
Why?
|
| Diabetes Complications | 1 | 2016 | 66 | 0.130 |
Why?
|
| Health Promotion | 2 | 2010 | 169 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2016 | 62 | 0.130 |
Why?
|
| Secondary Prevention | 2 | 2016 | 44 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2016 | 230 | 0.130 |
Why?
|
| Catheterization, Central Venous | 3 | 2012 | 36 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 151 | 0.130 |
Why?
|
| Morbidity | 2 | 2013 | 56 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2016 | 93 | 0.130 |
Why?
|
| Standard of Care | 1 | 2015 | 11 | 0.130 |
Why?
|
| International Classification of Diseases | 2 | 2012 | 32 | 0.130 |
Why?
|
| Mastectomy, Segmental | 1 | 2015 | 18 | 0.130 |
Why?
|
| Smoking | 4 | 2014 | 465 | 0.120 |
Why?
|
| Incidence | 6 | 2016 | 545 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 143 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 496 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 187 | 0.120 |
Why?
|
| Syndrome | 4 | 2016 | 78 | 0.120 |
Why?
|
| Mutation | 1 | 2019 | 817 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 464 | 0.120 |
Why?
|
| Ribosomes | 1 | 2015 | 31 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 338 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2012 | 85 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 284 | 0.120 |
Why?
|
| Culture | 1 | 2014 | 26 | 0.120 |
Why?
|
| Violence | 1 | 2014 | 31 | 0.120 |
Why?
|
| Albuminuria | 1 | 2014 | 23 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 218 | 0.110 |
Why?
|
| Goals | 1 | 2014 | 33 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 6 | 0.110 |
Why?
|
| Peer Group | 6 | 2012 | 36 | 0.110 |
Why?
|
| Antibodies | 2 | 2015 | 124 | 0.110 |
Why?
|
| Neoplasms | 3 | 2018 | 755 | 0.110 |
Why?
|
| Self Concept | 1 | 2014 | 52 | 0.110 |
Why?
|
| Diarrhea | 3 | 2010 | 53 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 50 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2014 | 111 | 0.110 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 125 | 0.110 |
Why?
|
| Income | 2 | 2011 | 38 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2013 | 41 | 0.110 |
Why?
|
| Neutropenia | 1 | 2013 | 35 | 0.110 |
Why?
|
| Social Conditions | 1 | 2013 | 5 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2013 | 58 | 0.110 |
Why?
|
| Conflict of Interest | 1 | 2013 | 15 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2019 | 276 | 0.110 |
Why?
|
| Obesity | 1 | 2018 | 650 | 0.100 |
Why?
|
| Heart Diseases | 2 | 2016 | 68 | 0.100 |
Why?
|
| Physicians | 2 | 2014 | 80 | 0.100 |
Why?
|
| Clinical Protocols | 2 | 2017 | 45 | 0.100 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 13 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 189 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 19 | 0.100 |
Why?
|
| Blood Coagulation Tests | 1 | 2012 | 27 | 0.100 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 35 | 0.100 |
Why?
|
| Internal-External Control | 2 | 2009 | 17 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 747 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 288 | 0.100 |
Why?
|
| Survival Rate | 4 | 2017 | 406 | 0.100 |
Why?
|
| Plateletpheresis | 1 | 2011 | 1 | 0.100 |
Why?
|
| Heparin | 1 | 2012 | 110 | 0.100 |
Why?
|
| Cardiac Catheterization | 1 | 2012 | 112 | 0.100 |
Why?
|
| Blood Donors | 1 | 2011 | 4 | 0.100 |
Why?
|
| Blood Preservation | 1 | 2011 | 9 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 74 | 0.100 |
Why?
|
| School Health Services | 1 | 2012 | 34 | 0.090 |
Why?
|
| Rho(D) Immune Globulin | 3 | 2013 | 12 | 0.090 |
Why?
|
| Factor Xa Inhibitors | 1 | 2012 | 53 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 288 | 0.090 |
Why?
|
| Time Factors | 5 | 2017 | 1562 | 0.090 |
Why?
|
| Schools | 1 | 2012 | 70 | 0.090 |
Why?
|
| Asian Americans | 1 | 2011 | 40 | 0.090 |
Why?
|
| Escherichia coli O157 | 2 | 2008 | 24 | 0.090 |
Why?
|
| Escherichia coli Infections | 2 | 2008 | 44 | 0.090 |
Why?
|
| Social Marketing | 1 | 2010 | 6 | 0.090 |
Why?
|
| Fatigue | 1 | 2011 | 57 | 0.090 |
Why?
|
| Methods | 1 | 2010 | 27 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 13 | 0.090 |
Why?
|
| Data Mining | 1 | 2010 | 15 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2015 | 398 | 0.090 |
Why?
|
| Patient Satisfaction | 4 | 2017 | 89 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 43 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2019 | 68 | 0.090 |
Why?
|
| Alcoholism | 2 | 2008 | 116 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 442 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 40 | 0.080 |
Why?
|
| Gender Identity | 1 | 2009 | 20 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 44 | 0.080 |
Why?
|
| Health Surveys | 4 | 2011 | 77 | 0.080 |
Why?
|
| Carbonic Anhydrases | 1 | 2009 | 6 | 0.080 |
Why?
|
| Kidney Pelvis | 1 | 2009 | 5 | 0.080 |
Why?
|
| Epidemiologic Research Design | 1 | 2009 | 10 | 0.080 |
Why?
|
| Age Distribution | 3 | 2015 | 70 | 0.080 |
Why?
|
| Urologic Neoplasms | 1 | 2009 | 13 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 107 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2009 | 87 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2009 | 54 | 0.080 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2009 | 36 | 0.080 |
Why?
|
| Self Report | 2 | 2021 | 116 | 0.080 |
Why?
|
| Memory | 1 | 2008 | 71 | 0.080 |
Why?
|
| Warfarin | 1 | 2009 | 94 | 0.080 |
Why?
|
| Physical Endurance | 1 | 2008 | 86 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2009 | 118 | 0.070 |
Why?
|
| Religion | 3 | 2020 | 23 | 0.070 |
Why?
|
| Psychometrics | 4 | 2013 | 117 | 0.070 |
Why?
|
| Enterocolitis | 1 | 2007 | 4 | 0.070 |
Why?
|
| Attention | 1 | 2008 | 90 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 45 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 54 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2009 | 145 | 0.070 |
Why?
|
| Maryland | 2 | 2018 | 7 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2007 | 16 | 0.070 |
Why?
|
| Self-Help Groups | 2 | 2007 | 15 | 0.070 |
Why?
|
| Community Health Services | 1 | 2007 | 31 | 0.070 |
Why?
|
| California | 2 | 2018 | 65 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2017 | 390 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2007 | 36 | 0.070 |
Why?
|
| Risk | 2 | 2017 | 133 | 0.070 |
Why?
|
| International Agencies | 2 | 2019 | 6 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2006 | 4 | 0.070 |
Why?
|
| Walking | 1 | 2007 | 130 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2013 | 263 | 0.070 |
Why?
|
| Juvenile Delinquency | 1 | 2005 | 4 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 377 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2011 | 367 | 0.060 |
Why?
|
| Aggression | 1 | 2005 | 25 | 0.060 |
Why?
|
| Data Collection | 2 | 2017 | 101 | 0.060 |
Why?
|
| Hirsutism | 1 | 2005 | 17 | 0.060 |
Why?
|
| Hair | 1 | 2005 | 15 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2005 | 53 | 0.060 |
Why?
|
| Fever | 2 | 2016 | 30 | 0.060 |
Why?
|
| Cognition | 1 | 2008 | 294 | 0.060 |
Why?
|
| Sensation Disorders | 1 | 2004 | 2 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 17 | 0.060 |
Why?
|
| Rural Health | 1 | 2004 | 15 | 0.060 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2005 | 63 | 0.060 |
Why?
|
| Poverty Areas | 1 | 2004 | 8 | 0.060 |
Why?
|
| Monitoring, Ambulatory | 1 | 2004 | 26 | 0.060 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2004 | 10 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2004 | 61 | 0.060 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2014 | 8 | 0.060 |
Why?
|
| Disease Management | 2 | 2003 | 84 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 1259 | 0.060 |
Why?
|
| Motor Activity | 1 | 2004 | 146 | 0.050 |
Why?
|
| Achievement | 1 | 2003 | 13 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 563 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2010 | 700 | 0.050 |
Why?
|
| Thrombin | 1 | 2003 | 68 | 0.050 |
Why?
|
| Quinazolinones | 1 | 2022 | 4 | 0.050 |
Why?
|
| Purines | 1 | 2022 | 14 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 14 | 0.050 |
Why?
|
| Activated Protein C Resistance | 1 | 2002 | 2 | 0.050 |
Why?
|
| Factor V | 1 | 2002 | 14 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 73 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 262 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2002 | 10 | 0.050 |
Why?
|
| HELLP Syndrome | 1 | 2001 | 5 | 0.050 |
Why?
|
| Tobacco Use Cessation | 1 | 2002 | 25 | 0.050 |
Why?
|
| Trust | 1 | 2021 | 21 | 0.050 |
Why?
|
| Blood Coagulation | 2 | 2018 | 116 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2017 | 52 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2002 | 64 | 0.050 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 9 | 0.050 |
Why?
|
| Mentors | 1 | 2021 | 31 | 0.050 |
Why?
|
| Choice Behavior | 2 | 2013 | 28 | 0.050 |
Why?
|
| Decision Making | 1 | 2003 | 169 | 0.050 |
Why?
|
| Cause of Death | 2 | 2013 | 66 | 0.050 |
Why?
|
| Lung | 1 | 2004 | 349 | 0.050 |
Why?
|
| Smoking Prevention | 1 | 2002 | 87 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2001 | 6 | 0.050 |
Why?
|
| Parity | 1 | 2021 | 48 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2021 | 63 | 0.050 |
Why?
|
| Social Responsibility | 2 | 2012 | 11 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 42 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2020 | 32 | 0.040 |
Why?
|
| Drug Hypersensitivity | 2 | 2016 | 22 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 310 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2015 | 209 | 0.040 |
Why?
|
| Hemostasis | 1 | 2020 | 47 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 240 | 0.040 |
Why?
|
| Family Planning Services | 1 | 2020 | 5 | 0.040 |
Why?
|
| Urban Population | 3 | 2006 | 70 | 0.040 |
Why?
|
| Religion and Psychology | 1 | 2020 | 9 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2020 | 27 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 47 | 0.040 |
Why?
|
| Pelvis | 1 | 2019 | 37 | 0.040 |
Why?
|
| Exercise | 1 | 2004 | 451 | 0.040 |
Why?
|
| Patient Admission | 1 | 2000 | 28 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 270 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 207 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 39 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 41 | 0.040 |
Why?
|
| Students | 1 | 2001 | 188 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2000 | 76 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 2 | 2013 | 46 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 68 | 0.040 |
Why?
|
| Chorionic Villi | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 20 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 15 | 0.040 |
Why?
|
| Interview, Psychological | 2 | 2013 | 12 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 14 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 172 | 0.040 |
Why?
|
| Pediatrics | 1 | 2000 | 87 | 0.040 |
Why?
|
| Capillaries | 1 | 2018 | 32 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2019 | 183 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 139 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2018 | 37 | 0.040 |
Why?
|
| Algorithms | 1 | 2001 | 419 | 0.040 |
Why?
|
| Species Specificity | 1 | 2018 | 186 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 121 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 108 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 108 | 0.040 |
Why?
|
| Oncologists | 1 | 2018 | 15 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 198 | 0.040 |
Why?
|
| Dideoxynucleosides | 1 | 2017 | 12 | 0.040 |
Why?
|
| Sexuality | 1 | 2017 | 4 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2018 | 116 | 0.040 |
Why?
|
| Safe Sex | 1 | 2017 | 7 | 0.040 |
Why?
|
| Leisure Activities | 2 | 2009 | 15 | 0.040 |
Why?
|
| Body Weight | 1 | 2018 | 246 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 7 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2017 | 132 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 104 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2018 | 134 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 125 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 33 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2017 | 75 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 119 | 0.040 |
Why?
|
| Gestational Age | 1 | 2017 | 140 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 80 | 0.030 |
Why?
|
| Diet | 1 | 2018 | 223 | 0.030 |
Why?
|
| Creatinine | 2 | 2009 | 57 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 8 | 0.030 |
Why?
|
| CD52 Antigen | 1 | 2016 | 3 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 2016 | 12 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 32 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 158 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 58 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 13 | 0.030 |
Why?
|
| Chills | 1 | 2016 | 3 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2016 | 7 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 13 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 36 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 75 | 0.030 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 13 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 25 | 0.030 |
Why?
|
| Urban Health | 2 | 2007 | 12 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 10 | 0.030 |
Why?
|
| Beverages | 1 | 2016 | 24 | 0.030 |
Why?
|
| Blindness | 1 | 2016 | 34 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 23 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2016 | 33 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 134 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2016 | 72 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2016 | 118 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 121 | 0.030 |
Why?
|
| Convalescence | 1 | 2015 | 6 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2015 | 25 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 771 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2015 | 67 | 0.030 |
Why?
|
| Pentostatin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Wisconsin | 1 | 2015 | 8 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 23 | 0.030 |
Why?
|
| Medicaid | 1 | 2015 | 52 | 0.030 |
Why?
|
| Hospice Care | 1 | 2015 | 15 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 60 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 49 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 51 | 0.030 |
Why?
|
| Medicare | 1 | 2015 | 118 | 0.030 |
Why?
|
| Vancomycin | 1 | 2015 | 56 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 60 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2015 | 63 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2015 | 55 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 275 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 48 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1475 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 207 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 237 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 19 | 0.030 |
Why?
|
| Japan | 1 | 2013 | 21 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 20 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 406 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2013 | 4 | 0.030 |
Why?
|
| Mortality | 1 | 2013 | 43 | 0.030 |
Why?
|
| Financial Support | 1 | 2013 | 9 | 0.030 |
Why?
|
| Family Relations | 1 | 2013 | 11 | 0.030 |
Why?
|
| Internationality | 1 | 2013 | 31 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2004 | 144 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 153 | 0.030 |
Why?
|
| Steroids | 1 | 2013 | 54 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 646 | 0.030 |
Why?
|
| Prothrombin | 2 | 2003 | 15 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 665 | 0.030 |
Why?
|
| Outpatients | 1 | 2012 | 42 | 0.030 |
Why?
|
| Inpatients | 1 | 2012 | 56 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 83 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 623 | 0.020 |
Why?
|
| Critical Care | 1 | 2011 | 48 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2001 | 19 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 56 | 0.020 |
Why?
|
| Kuwait | 1 | 2010 | 3 | 0.020 |
Why?
|
| Focus Groups | 1 | 2010 | 89 | 0.020 |
Why?
|
| Social Identification | 1 | 2009 | 4 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 96 | 0.020 |
Why?
|
| Socialization | 1 | 2009 | 6 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 15 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 225 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 45 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2010 | 172 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2009 | 3 | 0.020 |
Why?
|
| Censuses | 1 | 2009 | 3 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2009 | 27 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2009 | 23 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2009 | 12 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 65 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 66 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 39 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 72 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 253 | 0.020 |
Why?
|
| Switzerland | 1 | 2008 | 5 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 77 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 66 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2009 | 235 | 0.020 |
Why?
|
| Cholestasis | 1 | 2007 | 10 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 503 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 80 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 162 | 0.020 |
Why?
|
| Sports | 1 | 2005 | 23 | 0.020 |
Why?
|
| Education | 1 | 2005 | 33 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 20 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 9960 | 0.020 |
Why?
|
| Proprioception | 1 | 2004 | 5 | 0.010 |
Why?
|
| Restless Legs Syndrome | 1 | 2004 | 3 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2004 | 21 | 0.010 |
Why?
|
| Ankle | 1 | 2004 | 20 | 0.010 |
Why?
|
| Touch | 1 | 2004 | 12 | 0.010 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2004 | 9 | 0.010 |
Why?
|
| Weights and Measures | 1 | 2004 | 2 | 0.010 |
Why?
|
| Postural Balance | 1 | 2004 | 38 | 0.010 |
Why?
|
| MEDLINE | 1 | 2004 | 26 | 0.010 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2004 | 12 | 0.010 |
Why?
|
| Tomography, Spiral Computed | 1 | 2004 | 8 | 0.010 |
Why?
|
| Gait | 1 | 2004 | 58 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 56 | 0.010 |
Why?
|
| Models, Psychological | 1 | 2004 | 80 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 41 | 0.010 |
Why?
|
| Vibration | 1 | 2004 | 78 | 0.010 |
Why?
|
| Reflex | 1 | 2004 | 74 | 0.010 |
Why?
|
| Poverty | 1 | 2004 | 81 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2004 | 86 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2005 | 162 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 388 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 132 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2003 | 35 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2004 | 386 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 508 | 0.010 |
Why?
|
| Amino Acids | 1 | 2003 | 80 | 0.010 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2002 | 1 | 0.010 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2002 | 3 | 0.010 |
Why?
|
| 3' Untranslated Regions | 1 | 2002 | 33 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 176 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 148 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2002 | 182 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 197 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 189 | 0.010 |
Why?
|
| Histocompatibility | 1 | 2001 | 4 | 0.010 |
Why?
|
| Microcirculation | 1 | 2002 | 111 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 262 | 0.010 |
Why?
|
| Aphasia, Broca | 1 | 2001 | 2 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 68 | 0.010 |
Why?
|
| Amnesia | 1 | 2001 | 9 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 30 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2001 | 25 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 442 | 0.010 |
Why?
|
| Fungemia | 1 | 2000 | 5 | 0.010 |
Why?
|
| Bacteremia | 1 | 2000 | 80 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 604 | 0.010 |
Why?
|
| Pain | 1 | 2001 | 252 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 578 | 0.010 |
Why?
|